Exelixis
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 1.3K
- Market Cap
- $7.3B
- Website
- http://www.exelixis.com
- Introduction
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
- Conditions
- Hepatic ImpairmentModerate Hepatic Impairment
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 20
- Registration Number
- NCT06962332
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
- Conditions
- Solid TumorMetastatic Solid TumorAdvanced Solid TumorImmune Sensitive Tumor
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 75
- Registration Number
- NCT06952010
- Locations
- 🇺🇸
Exelixis Clinical Site #1, Hickory, North Carolina, United States
🇺🇸Exelixis Clinical Site #2, San Antonio, Texas, United States
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Conditions
- Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 440
- Registration Number
- NCT06943755
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Solid CancersSolid Tumor CancerSolid Tumor MalignancyUrothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)Metastatic Solid TumorLocally Advanced Solid TumorUrothelial Cancer of Renal Pelvis
- Interventions
- Drug: ADC cytotoxic agents
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 124
- Registration Number
- NCT06630247
- Locations
- 🇺🇸
Exelixis Clinical Site #10, Jefferson, Louisiana, United States
🇺🇸Exelixis Clinical Site #4, Denver, Colorado, United States
🇺🇸Exelixis Clinical Site #9, New Haven, Connecticut, United States
Study of XB010 in Subjects With Solid Tumors
- Conditions
- Locally Advanced or Metastatic Solid TumorsEsophageal Squamous Cell CancerHead and Neck Squamous Cell CancerNSCLC (Non-small Cell Lung Cancer)Hormone-receptor-positive Breast CancerTriple Negative Breast Cancer (TNBC)
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 396
- Registration Number
- NCT06545331
- Locations
- 🇺🇸
Exelixis Clinical Site #7, Dallas, Texas, United States
🇺🇸Exelixis Clinical Site #8, Houston, Texas, United States
🇺🇸Exelixis Clinical Site #4, Duarte, California, United States
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 140
- Registration Number
- NCT06191796
- Locations
- 🇺🇸
Exelixis Site #8, Los Angeles, California, United States
🇺🇸Exelixis Site #9, Miami, Florida, United States
🇺🇸Exelixis Clinical Site #1, Orlando, Florida, United States
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 600
- Registration Number
- NCT06082167
- Locations
- 🇲🇽
Exelixis Clinical Site #168, Guadalajara, Mexico
🇺🇸Exelixis Clinical Site #2, Fullerton, California, United States
🇺🇸Exelixis Clinical Site #1, Orange City, Florida, United States
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 425
- Registration Number
- NCT05932862
- Locations
- 🇺🇸
Exelixis Clinical Site #12, Fountain Valley, California, United States
🇺🇸Exelixis Clinical Site #15, Jacksonville, Florida, United States
🇺🇸Exelixis Clinical Site #8, Orlando, Florida, United States
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
- Conditions
- Non-Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 291
- Registration Number
- NCT05678673
- Locations
- 🇺🇸
Exelixis Clinical Site #164, Newport Beach, California, United States
🇺🇸Exelixis Clinical Site #162, San Francisco, California, United States
🇺🇸Exelixis Clinical Site #163, Aurora, Colorado, United States
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 874
- Registration Number
- NCT05425940
- Locations
- 🇺🇸
Exelixis Clinical Site #77, Los Angeles, California, United States
🇺🇸Exelixis Clinical Site #106, Philadelphia, Pennsylvania, United States
🇺🇸Exelixis Clinical Site #103, Pittsburgh, Pennsylvania, United States